Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Oct 20, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Tecentriq (Presentation of Latest Data as an Adjuvant Treatment in Muscle-Invasive Bladder Cancer at ESMO)
TOKYO, October 20, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today, including the latest data of Tecentriq® (atezolizumab) as an adjuvant treatment for muscle-invasive bladder cancer, presented at the European Society for Medical Oncology Congress (ESMO) 2025.
Please refer to the link below for details of the press release:
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
https://www.roche.com/media/releases/med-cor-2025-10-20b
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp